Please assess the completion status of the following clinical trial:

Trial Title: Carnitine Infusion and Insulin Resistance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* • Caucasian~  * Healthy (as determined by responsible physician based on a medical questionnaire)~ * Male~ * Age: 18-40 years~ * Normal BMI: 18-25 kg/m2~ * Stable dietary habits~ * No use of medication interfering with investigated study parameters (as determined by responsible physician)~Exclusion Criteria:~* • Female~  * Haemoglobin levels \< 7.8 mmol/L~ * Uncontrolled hypertension~ * Use of anticoagulants~ * Engagement in exercise \> 3 hours a week~ * Being vegetarian or vegan (because of altered whole body carnitine status)~ * Smoking~ * Alcohol and/or drug abuse~ * Unstable body weight (weight gain or loss \> 5kg in the last 3 months)~ * Significant food allergies/intolerances (seriously hampering study meals)~ * Participation in another biomedical study within 1 month before the first study visit, which would possibly hamper our study results~ * Medication use known to hamper subject's safety during the study procedures~ * Medication use known to interfere with investigated study parameters~ * Subjects with contra-indications for MRI~ * Subjects who intend to donate blood during the intervention or subjects who have donated blood less than three months before the start of the study~ * Subjects who do not want to be informed about unexpected medical findings~ * Subjects who do not want that their treating physician is informed

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- LIPID + Carnitor (Type: EXPERIMENTAL): intravenous Lipid infusion (IntraLipid) combined with carnitor (L-carnitine) infusion~L-Carnitine will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The administration will start with a bolus of 15mg/kg for 10 minutes. Subsequently, continuous L-carnitine infusion of 10mg/kg will start for the remaining 350 minutes.~Intralipid will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The maximum dosage will not exceed 90 mL/h.
- LIPID + PLAC (Type: PLACEBO_COMPARATOR): Intravenous Lipid infusion (IntraLipid) combined with placebo infusion (saline)~Intralipid will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The maximum dosage will not exceed 90 mL/h.
- PLAC (Type: PLACEBO_COMPARATOR): Infusion of saline (no IntraLipid and no carnitor)~Saline will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The maximum dosage will not exceed 90 ml/h.

Based on this trial design, predict the completion outcome and termination type (if applicable).